CLYDE HOSEIN, a director at $XRAY, bought 6,500 shares of the company on 06-15-2026 for an estimated $64,902. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 10.1%. Following this trade, they now own 70,575 shares of this class of $XRAY stock.
$XRAY Insider Trading Activity
$XRAY insiders have traded $XRAY stock on the open market 9 times in the past 6 months. Of those trades, 9 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $XRAY stock by insiders over the last 6 months:
- GREGORY T LUCIER has made 3 purchases buying 65,000 shares for an estimated $894,054 and 0 sales.
- MICHAEL J BARBER purchased 15,175 shares for an estimated $150,004
- BRIAN P MCKEON purchased 10,000 shares for an estimated $101,199
- BRIAN T GLADDEN purchased 9,985 shares for an estimated $99,999
- BETSY D HOLDEN purchased 10,086 shares for an estimated $99,692
- CLYDE HOSEIN purchased 6,500 shares for an estimated $64,902
- JAMES D FORBES purchased 5,000 shares for an estimated $62,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$XRAY Hedge Fund Activity
We have seen 209 institutional investors add shares of $XRAY stock to their portfolio, and 239 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOUTHPOINT CAPITAL ADVISORS LP added 10,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $116,000,000
- ARMISTICE CAPITAL, LLC removed 4,298,000 shares (-58.9%) from their portfolio in Q1 2026, for an estimated $49,856,800
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 2,399,725 shares (-76.9%) from their portfolio in Q1 2026, for an estimated $27,836,810
- FREESTONE GROVE PARTNERS LP added 2,297,378 shares (+inf%) to their portfolio in Q1 2026, for an estimated $26,649,584
- MARSHALL WACE, LLP added 2,271,616 shares (+101.6%) to their portfolio in Q1 2026, for an estimated $26,350,745
- NORGES BANK removed 2,203,362 shares (-88.1%) from their portfolio in Q4 2025, for an estimated $25,184,427
- NEUBERGER BERMAN GROUP LLC added 1,900,712 shares (+inf%) to their portfolio in Q1 2026, for an estimated $22,048,259
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$XRAY Revenue
$XRAY had revenues of $880M in Q1 2026. This is an increase of 0.11% from the same period in the prior year.
You can track XRAY financials on Quiver Quantitative's XRAY stock page.
You can access data on XRAY stock through the Quiver Quantitative API.
$XRAY Analyst Ratings
Wall Street analysts have issued reports on $XRAY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Underweight" rating on 06/04/2026
- Barrington Research issued a "Outperform" rating on 01/05/2026
To track analyst ratings and price targets for $XRAY, check out Quiver Quantitative's $XRAY forecast page.
$XRAY Price Targets
Multiple analysts have issued price targets for $XRAY recently. We have seen 9 analysts offer price targets for $XRAY in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $9.0 on 06/04/2026
- Kevin Caliendo from UBS set a target price of $17.0 on 05/07/2026
- Steven Valiquette from Mizuho set a target price of $14.0 on 05/06/2026
- Daniel Grosslight from Citigroup set a target price of $10.0 on 04/15/2026
- Michael Petusky from Barrington Research set a target price of $17.0 on 03/02/2026
- Jeffrey Johnson from Baird set a target price of $14.0 on 02/27/2026
- Elizabeth Anderson from Evercore ISI Group set a target price of $15.0 on 02/27/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
